

Dawn C Buse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2980612/publications.pdf>

Version: 2024-02-01

162
papers

9,714
citations

34076

52
h-index

43868

91
g-index

167
all docs

167
docs citations

167
times ranked

4438
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic Migraine Prevalence, Disability, and Sociodemographic Factors: Results From the American Migraine Prevalence and Prevention Study. <i>Headache</i> , 2012, 52, 1456-1470.	1.8	389
2	Migraine. <i>Neurologic Clinics</i> , 2019, 37, 631-649.	0.8	358
3	Sex Differences in the Prevalence, Symptoms, and Associated Features of Migraine, Probable Migraine and Other Severe Headache: Results of the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2013, 53, 1278-1299.	1.8	330
4	Migraine: epidemiology and systems of care. <i>Lancet, The</i> , 2021, 397, 1485-1495.	6.3	310
5	Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS). <i>Headache</i> , 2013, 53, 644-655.	1.8	295
6	Psychiatric comorbidities of episodic and chronic migraine. <i>Journal of Neurology</i> , 2013, 260, 1960-1969.	1.8	283
7	Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. <i>Neurology</i> , 2015, 84, 688-695.	1.5	219
8	Depression and risk of transformation of episodic to chronic migraine. <i>Journal of Headache and Pain</i> , 2012, 13, 615-624.	2.5	214
9	Defining the Differences Between Episodic Migraine and Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2012, 16, 86-92.	1.3	211
10	Cost of Health Care Among Patients With Chronic and Episodic Migraine in Canada and the USA: Results From the International Burden of Migraine Study (IBMS). <i>Headache</i> , 2011, 51, 1058-1077.	1.8	204
11	The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. <i>Cephalalgia</i> , 2015, 35, 563-578.	1.8	203
12	Migraine Progression: A Systematic Review. <i>Headache</i> , 2019, 59, 306-338.	1.8	198
13	Assessing and Managing All Aspects of Migraine: Migraine Attacks, Migraine-Related Functional Impairment, Common Comorbidities, and Quality of Life. <i>Mayo Clinic Proceedings</i> , 2009, 84, 422-435.	1.4	180
14	Chronic Migraine: Epidemiology and Disease Burden. <i>Current Pain and Headache Reports</i> , 2011, 15, 70-78.	1.3	176
15	Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2016, 56, 821-834.	1.8	160
16	Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. <i>Journal of Headache and Pain</i> , 2017, 18, 101.	2.5	158
17	Employment and Work Impact of Chronic Migraine and Episodic Migraine. <i>Journal of Occupational and Environmental Medicine</i> , 2010, 52, 8-14.	0.9	148
18	Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey. <i>Headache</i> , 2016, 56, 306-322.	1.8	147

#	ARTICLE	IF	CITATIONS
19	Barriers to the Diagnosis and Treatment of Migraine: Effects of Sex, Income, and Headache Features. Headache, 2013, 53, 81-92.	1.8	144
20	Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. Journal of Headache and Pain, 2020, 21, 23.	2.5	143
21	Migraine: integrated approaches to clinical management and emerging treatments. Lancet, The, 2021, 397, 1505-1518.	6.3	139
22	Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache, 2019, 59, 1286-1299.	1.8	135
23	Assessing and Managing All Aspects of Migraine: Migraine Attacks, Migraine-Related Functional Impairment, Common Comorbidities, and Quality of Life. Mayo Clinic Proceedings, 2009, 84, 422-435.	1.4	134
24	Examination of Unmet Treatment Needs Among Persons With Episodic Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache, 2013, 53, 1300-1311.	1.8	128
25	A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability. Headache, 2016, 56, 1280-1289.	1.8	127
26	Reduction in perceived stress as a migraine trigger. Neurology, 2014, 82, 1395-1401.	1.5	123
27	Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study. Mayo Clinic Proceedings, 2016, 91, 596-611.	1.4	123
28	Trigger Factors and Premonitory Features of Migraine Attacks: Summary of Studies. Headache, 2014, 54, 1670-1679.	1.8	111
29	Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences. Headache, 2018, 58, 1408-1426.	1.8	106
30	Opioid Use and Dependence Among Persons With Migraine: Results of the AMPP Study. Headache, 2012, 52, 18-36.	1.8	103
31	Cost and Predictors of Lost Productive Time in Chronic Migraine and Episodic Migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Value in Health, 2013, 16, 31-38.	0.1	99
32	Behavioral Medicine for Migraine. Neurologic Clinics, 2009, 27, 445-465.	0.8	96
33	Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. Journal of Headache and Pain, 2018, 19, 38.	2.5	88
34	Methodological Issues in Studying Trigger Factors and Premonitory Features of Migraine. Headache, 2014, 54, 1661-1669.	1.8	84
35	Headache as a side effect of combination estrogen-progestin oral contraceptives: A systematic review. American Journal of Obstetrics and Gynecology, 2005, 193, 636-649.	0.7	81
36	Pain, Psychological Comorbidities, Disability, and Impaired Quality of Life in Hidradenitis Suppurativa. Current Pain and Headache Reports, 2017, 21, 49.	1.3	77

#	ARTICLE	IF	CITATIONS
37	Nonpharmacologic Treatments for Migraine and Tension-Type Headache: How to Choose and When to Use. <i>Current Treatment Options in Neurology</i> , 2011, 13, 28-40.	0.7	76
38	Tension-type headache. <i>Nature Reviews Disease Primers</i> , 2021, 7, 24.	18.1	75
39	Perimenopause and Menopause Are Associated With High Frequency Headache in Women With Migraine: Results of the American Migraine Prevalence and Prevention Study. <i>Headache</i> , 2016, 56, 292-305.	1.8	73
40	Psychological Factors Associated With Chronic Migraine and Severe Migraine-Related Disability: An Observational Study in a Tertiary Headache Center. <i>Headache</i> , 2017, 57, 593-604.	1.8	71
41	Recalled maltreatment, migraine, and tension-type headache. <i>Neurology</i> , 2015, 84, 132-140.	1.5	66
42	Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2016, 56, 1635-1648.	1.8	64
43	Sleep Disorders Among People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2019, 59, 32-45.	1.8	63
44	Does Mindfulness-Based Cognitive Therapy for Migraine Reduce Migraine-Related Disability in People with Episodic and Chronic Migraine? A Phase 2b Pilot Randomized Clinical Trial. <i>Headache</i> , 2019, 59, 1448-1467.	1.8	62
45	Comorbid pain and migraine chronicity. <i>Neurology</i> , 2017, 89, 461-468.	1.5	61
46	Identifying Natural Subgroups of Migraine Based on Comorbidity and Concomitant Condition Profiles: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2018, 58, 933-947.	1.8	61
47	Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study. <i>Headache</i> , 2020, 60, 416-429.	1.8	61
48	Burden of migraine related to menses: results from the AMPP study. <i>Journal of Headache and Pain</i> , 2015, 16, 24.	2.5	60
49	Migraine progression in subgroups of migraine based on comorbidities. <i>Neurology</i> , 2019, 93, e2224-e2236.	1.5	60
50	The International Burden of Migraine Study (IBMS): Study design, methodology, and baseline cohort characteristics. <i>Cephalalgia</i> , 2011, 31, 1116-1130.	1.8	59
51	Why HURT? A Review of Clinical Instruments for Headache Management. <i>Current Pain and Headache Reports</i> , 2012, 16, 237-254.	1.3	59
52	Frequency and Burden of Headache-Related Nausea: Results From the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2013, 53, 93-103.	1.8	59
53	Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. <i>Cephalalgia</i> , 2018, 38, 1622-1631.	1.8	59
54	Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches. <i>Health and Quality of Life Outcomes</i> , 2016, 14, 143.	1.0	55

#	ARTICLE	IF	CITATIONS
55	Clinical Pain Catastrophizing in Women With Migraine and Obesity. <i>Headache</i> , 2015, 55, 923-933.	1.8	54
56	Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study. <i>Headache</i> , 2019, 59, 1310-1323.	1.8	54
57	Impact of <sc>NSAID</sc> and Triptan Use on Developing Chronic Migraine: Results From the <sc>A</sc>merican Migraine Prevalence and Prevention (<sc>AMPP</sc>) Study. <i>Headache</i> , 2013, 53, 1548-1563.	1.8	53
58	Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. <i>International Journal of General Medicine</i> , 2015, 8, 79.	0.8	51
59	Framinghamâ€Based Cardiovascular Risk Estimates Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2017, 57, 1507-1521.	1.8	51
60	Asthma is a risk factor for new onset chronic migraine: Results from the <sc>A</sc>merican migraine prevalence and prevention study. <i>Headache</i> , 2016, 56, 118-131.	1.8	49
61	Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study. <i>Headache</i> , 2017, 57, 1026-1040.	1.8	49
62	Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2017, 57, 31-44.	1.8	49
63	Characterizing opioid use in a US population with migraine. <i>Neurology</i> , 2020, 95, e457-e468.	1.5	48
64	Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 353-360.	0.9	47
65	Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2020, 60, 2340-2356.	1.8	47
66	Persistent Frequent Nausea Is Associated With Progression to Chronic Migraine: <sc>AMPP</sc> Study Results. <i>Headache</i> , 2015, 55, 76-87.	1.8	46
67	Headache and Combination Estrogenâ€Progestin Oral Contraceptives: Integrating Evidence, Guidelines, and Clinical Practice. <i>Headache</i> , 2005, 45, 224-231.	1.8	43
68	Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies. <i>Cephalgia</i> , 2020, 40, 503-516.	1.8	43
69	Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study. <i>Headache</i> , 2022, 62, 122-140.	1.8	43
70	Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM). <i>Cephalgia</i> , 2016, 36, 203-215.	1.8	42
71	The Effect of Psychiatric Comorbidities on Headacheâ€Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2020, 60, 1683-1696.	1.8	42
72	Behavioral Interventions for Migraine. <i>Neurologic Clinics</i> , 2019, 37, 789-813.	0.8	41

#	ARTICLE	IF	CITATIONS
73	Facilitating communication with patients for improved migraine outcomes. <i>Current Pain and Headache Reports</i> , 2008, 12, 230-236.	1.3	39
74	Depression and Anxiety in Episodic and Chronic Cluster Headache: A Pilot Study. <i>Headache</i> , 2012, 52, 600-611.	1.8	39
75	Global perspectives on the burden of episodic and chronic migraine. <i>Cephalalgia</i> , 2013, 33, 885-890.	1.8	38
76	Sex and Gender Differences in Migraine—Evaluating Knowledge Gaps. <i>Journal of Women's Health</i> , 2018, 27, 965-973.	1.5	38
77	Headache-related health resource utilisation in chronic and episodic migraine across six countries. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1309-1317.	0.9	36
78	Psychometric Evaluation of a Novel Instrument Assessing the Impact of Migraine on Physical Functioning: The Migraine Physical Function Impact Diary. <i>Headache</i> , 2017, 57, 1385-1398.	1.8	35
79	Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study. <i>Journal of Headache and Pain</i> , 2020, 21, 20.	2.5	35
80	Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study. <i>Headache</i> , 2021, 61, 628-641.	1.8	35
81	Chronic rhinitis and its association with headache frequency and disability in persons with migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. <i>Cephalalgia</i> , 2014, 34, 336-348.	1.8	34
82	Epidemiology of migraine in men: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Cephalalgia</i> , 2019, 39, 296-305.	1.8	34
83	Behavioral medicine for migraine and medication overuse headache. <i>Current Pain and Headache Reports</i> , 2009, 13, 241-248.	1.3	33
84	Rates and reasons for discontinuation of triptans and opioids in episodic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study. <i>Journal of the Neurological Sciences</i> , 2013, 326, 10-17.	0.3	33
85	Systematic review of outcomes and endpoints in acute migraine clinical trials. <i>Headache</i> , 2021, 61, 263-275.	1.8	33
86	Improving the Classification of Migraine Subtypes: An Empirical Approach Based on Factor Mixture Models in the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2014, 54, 830-849.	1.8	32
87	Acute Treatment Optimization in Episodic and Chronic Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2015, 55, 502-518.	1.8	32
88	Photophobia: shared pathophysiology underlying dry eye disease, migraine and traumatic brain injury leading to central neuroplasticity of the trigeminothalamic pathway. <i>British Journal of Ophthalmology</i> , 2021, 105, 751-760.	2.1	32
89	Behavioral Treatments for Migraine Management: Useful at Each Step of Migraine Care. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 14.	2.0	31
90	Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2019, 59, 1762-1772.	1.8	31

#	ARTICLE	IF	CITATIONS
91	Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale. <i>Headache</i> , 2017, 57, 570-585.	1.8	30
92	Development and exploration of the content validity of a patient-reported outcome measure to evaluate the impact of migraine- the migraine physical function impact diary (MPFID). <i>Health and Quality of Life Outcomes</i> , 2017, 15, 224.	1.0	29
93	Is there a causal relationship between stress and migraine? Current evidence and implications for management. <i>Journal of Headache and Pain</i> , 2021, 22, 155.	2.5	29
94	Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study. <i>Headache</i> , 2021, 61, 662-672.	1.8	27
95	Predictors of allodynia in persons with migraine: Results from the Migraine in America Symptoms and Treatment (MAST) study. <i>Cephalalgia</i> , 2019, 39, 873-882.	1.8	26
96	Factors Associated With Triptan Use in Episodic Migraine: Results From the American Migraine Prevalence and Prevention Study. <i>Headache</i> , 2012, 52, 213-223.	1.8	25
97	Improving Medical Communication in Migraine Management: A Modified Delphi Study to Develop a Digital Migraine Tracker. <i>Headache</i> , 2018, 58, 1358-1372.	1.8	25
98	Medication Overuse and Headache Burden. <i>Neurology: Clinical Practice</i> , 2021, 11, 216-226.	0.8	25
99	The Headache Under-Response to Treatment (HURT) Questionnaire: Assessment of utility in headache specialist care. <i>Cephalalgia</i> , 2013, 33, 245-255.	1.8	24
100	Learning the full impact of migraine through patient voices: A qualitative study. <i>Headache</i> , 2021, 61, 1004-1020.	1.8	24
101	United States Patients'™ Perspective of Living With Migraine: Country-specific Results From the Global "My Migraine Voice" Survey. <i>Headache</i> , 2020, 60, 1351-1364.	1.8	23
102	Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 1334-1343.	0.5	22
103	Rates and Predictors of Starting a Triptan: Results From the American Migraine Prevalence and Prevention Study. <i>Headache</i> , 2010, 50, 1440-1448.	1.8	21
104	Effects of Switching Acute Treatment on Disability in Migraine Patients Using Triptans. <i>Headache</i> , 2013, 53, 1415-1429.	1.8	21
105	Individuals with migraine have a different dry eye symptom profile than individuals without migraine. <i>British Journal of Ophthalmology</i> , 2020, 104, 260-264.	2.1	21
106	A Case Study for Calculating Employer Costs for Lost Productive Time in Episodic Migraine and Chronic Migraine. <i>Journal of Occupational and Environmental Medicine</i> , 2011, 53, 1161-1171.	0.9	20
107	Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study. <i>Headache</i> , 2015, 55, 825-839.	1.8	20
108	Ecological momentary assessment of the relationship between headache pain intensity and pain interference in women with migraine and obesity. <i>Cephalalgia</i> , 2016, 36, 1228-1237.	1.8	20

#	ARTICLE	IF	CITATIONS
109	Effect of fremanezumab on quality of life and productivity in patients with chronic migraine. <i>Neurology</i> , 2020, 95, e878-e888.	1.5	20
110	Evaluating the Psychometric Properties of the Migraine Functional Impact Questionnaire (MFIQ). <i>Headache</i> , 2019, 59, 1253-1269.	1.8	17
111	Adolescent Perspectives on the Burden of a Parent's Migraine: Results from the CaMEO Study. <i>Headache</i> , 2018, 58, 512-524.	1.8	16
112	Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes – The Migraine Functional Impact Questionnaire (MFIQ). <i>Headache</i> , 2018, 58, 1612-1628.	1.8	16
113	Childhood Maltreatment in the Migraine Patient. <i>Current Treatment Options in Neurology</i> , 2016, 18, 31.	0.7	15
114	The Association Between Parental Migraine and Infant Colic: A Cross-sectional, Web-based, U.S. Survey Study. <i>Headache</i> , 2019, 59, 988-1001.	1.8	14
115	Characterization of Acute Prescription Migraine Medication Use. <i>Mayo Clinic Proceedings</i> , 2020, 95, 709-718.	1.4	14
116	Patterns of Perceived Stress Throughout the Migraine Cycle: A Longitudinal Cohort Study Using Daily Prospective Diary Data. <i>Headache</i> , 2021, 61, 90-102.	1.8	14
117	Healthcare resource utilization and direct costs associated with frequent nausea in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. <i>Journal of Medical Economics</i> , 2013, 16, 490-499.	1.0	13
118	Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS Study. <i>Headache</i> , 2017, 57, 1570-1582.	1.8	12
119	When Mom Has Migraine: An Observational Study of the Impact of Parental Migraine on Adolescent Children. <i>Headache</i> , 2019, 59, 224-234.	1.8	12
120	Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study. <i>Journal of Headache and Pain</i> , 2020, 21, 109.	2.5	12
121	Erenumab patient characteristics, medication adherence, and treatment patterns in the United States. <i>Headache</i> , 2021, 61, 590-602.	1.8	12
122	Health-related quality of life in tension-type headache: a population-based study. <i>Scandinavian Journal of Pain</i> , 2021, 21, 778-787.	0.5	12
123	Longitudinal Change in Migraine Headache-Days and Indirect Cost Consequences. <i>Journal of Occupational and Environmental Medicine</i> , 2011, 53, 478-487.	0.9	11
124	Acceptance, Psychiatric Symptoms, and Migraine Disability: An Observational Study in a Headache Center. <i>Headache</i> , 2018, 58, 859-872.	1.8	11
125	AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial. <i>Headache</i> , 2018, 58, 229-242.	1.8	10
126	Optimism, Pessimism, and Migraine: A Cross-sectional, Population-Based Study. <i>Headache</i> , 2019, 59, 205-214.	1.8	10

#	ARTICLE	IF	CITATIONS
127	Efficacy and Feasibility of Behavioral Treatments for Migraine, Headache, and Pain in the Acute Care Setting. <i>Current Pain and Headache Reports</i> , 2020, 24, 66.	1.3	10
128	Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study. <i>Headache</i> , 2021, 61, 103-116.	1.8	10
129	Efficacy of erenumab in chronic migraine patients with and without ictal allodynia. <i>Cephalalgia</i> , 2021, 41, 1152-1160.	1.8	10
130	Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2. <i>Clinical Therapeutics</i> , 2022, 44, 389-402.	1.1	10
131	Assessing Physicianâ€Patient Dialogues About Chronic Migraine During Routine Office Visits. <i>Headache</i> , 2018, 58, 993-1006.	1.8	9
132	Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study. <i>Cephalalgia</i> , 2022, 42, 20-30.	1.8	9
133	Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine. <i>Journal of Headache and Pain</i> , 2022, 23, 29.	2.5	9
134	Assessing the quality of health-related quality of life measures. <i>Cephalalgia</i> , 2013, 33, 223-225.	1.8	8
135	Why Migraine Forecasting Matters. <i>Headache</i> , 2017, 57, 1023-1025.	1.8	8
136	The prevalence of hypnic headache in Iceland. <i>Cephalalgia</i> , 2020, 40, 863-865.	1.8	8
137	Improvements in quality of life and work productivity with up to 6Âmonths of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraineâ€preventive medications in the phase 3b FOCUS study. <i>Headache</i> , 2021, 61, 1376-1386.	1.8	8
138	Dating and Relationship Psychoeducational Group for Veterans with Spinal Cord Injury/Dysfunction: A Historical Account of an Initial Clinical Course. <i>Sexuality and Disability</i> , 2013, 31, 337-359.	0.4	7
139	Primary headache: Whatâ€™s stress got to do with it?. <i>Cephalalgia</i> , 2015, 35, 844-849.	1.8	7
140	Evaluating Mean Level and Withinâ€Person Consistency in Migraine Pain Intensity and Migraineâ€Related Disability for AVPâ€825 vs Oral Sumatriptan: Results from the COMPASS Study, A Randomized Trial. <i>Headache</i> , 2019, 59, 1002-1013.	1.8	7
141	The migraine signature study: Methods and baseline results. <i>Headache</i> , 2021, 61, 462-484.	1.8	7
142	Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study. <i>Journal of Headache and Pain</i> , 2022, 23, 22.	2.5	7
143	Predicting initiation of preventive migraine medications: exploratory study in a large U.S. medical claims database. <i>Current Medical Research and Opinion</i> , 2020, 36, 51-61.	0.9	6
144	Response to Mindfulness-Based Cognitive Therapy Differs Between Chronic and Episodic Migraine. <i>Neurology: Clinical Practice</i> , 2021, 11, 194-205.	0.8	6

#	ARTICLE	IF	CITATIONS
145	Combining Guided Intervention of Education and Relaxation (GIER) with Remote Electrical Neuromodulation (REN) in the Acute Treatment of Migraine. <i>Pain Medicine</i> , 2022, 23, 1544-1549.	0.9	6
146	Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE ² for research in migraine prevention. <i>Headache</i> , 2022, 62, 690-699.	1.8	6
147	The Biopsychosocial/Spiritual Impact of Chronic Pain, Chronic Illness, and Physical Disabilities in Adolescence. <i>Current Pain and Headache Reports</i> , 2015, 19, 51.	1.3	5
148	Ten Eleven Things Not to Say to Healthcare Professionals During the Coronavirus Disease 2019 Pandemic. <i>Headache</i> , 2020, 60, 1837-1845.	1.8	5
149	Predictive models for determining treatment response to nonprescription acute medications in migraine: Results from the American Migraine Prevalence and Prevention Study. <i>Headache</i> , 2022, 62, 755-765.	1.8	5
150	Predicting the Future of Migraine Attack Prediction. <i>Headache</i> , 2020, 60, 2125-2128.	1.8	4
151	The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642210959.	1.5	4
152	Migraine Progression: A Systematic Review. An Editorial Comment. <i>Headache</i> , 2019, 59, 974-976.	1.8	3
153	Combining patient reported outcomes and EHR data to understand population level treatment needs: correcting for selection bias in the migraine signature study. <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 132.	0.9	3
154	Biobehavioral, Complementary and Alternative Treatments for Headache. , 2011, , 667-686.		2
155	The value of the patient perspective in understanding the full burden of migraine. <i>Headache</i> , 2021, 61, 985-987.	1.8	1
156	Comorbidities in children and adolescents. , 2022, , 79-99.		1
157	Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials. <i>Headache</i> , 2022, 62, 159-168.	1.8	1
158	Epidemiology of the psychiatric comorbidities of headache. , 0, , 1-8.		0
159	2015 <i>Headache</i> Membersâ€™ Choice Award. <i>Headache</i> , 2016, 56, 1088-1090.	1.8	0
160	Updated process for American Headache Society Guidelines. <i>Headache</i> , 2021, 61, 565-566.	1.8	0
161	Author response: Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study. <i>Neurology</i> , 2020, 95, 707-708.	1.5	0
162	Treatment Patterns and Unmet Needs in the Acute Treatment of Migraine. <i>Journal of Family Practice</i> , 2020, 69, S1-S7.	0.2	0